Skip to content

GPx Activity in Subjects With Aortic Stenosis Undergoing TAVR

Glutathione Peroxidase Activity in Subjects With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04268160
Enrollment
0
Registered
2020-02-13
Start date
2020-11-30
Completion date
2021-06-15
Last updated
2021-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Stenosis, Glutathione Peroxidase Activity, Transcatheter Aortic Valve Replacement

Keywords

glutathione peroxidase, GPx, aortic stenosis, transcatheter aortic valve replacement, TAVR

Brief summary

The aim of this project is to investigate the association of glutathione peroxidase (GPx) and severe aortic stenosis (AS), as well as the impact of transcatheter aortic valve replacement (TAVR) on GPx activity post-procedure. The burden of oxidative stress will be determined by the measurement of GPx, superoxide dismutase (SOD) and lipoprotein A (Lp(a)). We hypothesize GPx activity is reduced in participants with severe AS vs control groups and GPx activity is to increase after TAVR is performed.

Interventions

DIAGNOSTIC_TESTBlood draw to measure GPx activity

Routine blood draw to measure levels of blood markers.

DIAGNOSTIC_TESTBlood draw to measure SOD activity

Routine blood draw to measure levels of blood markers.

DIAGNOSTIC_TESTBlood draw to measure Lp(a) levels

Routine blood draw to measure levels of blood markers.

Sponsors

University of Florida
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \>18 years * Patients with severe AS including participants with low flow, low gradient severe AS and paradoxical severe AS * Patients meeting criteria for TAVR procedure

Exclusion criteria

* Previous aortic valve replacement (surgical or TAVR) * Participants undergoing chemotherapy * End stage liver disease/cirrhosis (liver produces GSH)

Design outcomes

Primary

MeasureTime frameDescription
Level of GPx in blood samplesBaseline up to 6 monthsGlutathione peroxidase activity levels measured from whole blood in U/L units in participants with severe aortic stenosis after transcatheter valve replacement compared with the matched population

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026